Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture

NCT03451916 is registered in ClinicalTrials.gov with Pluristem Ltd. as lead sponsor.

NCT NCT03451916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03451916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture
Lead sponsor
Pluristem Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 26, 2018
Completion date
September 6, 2023
Enrollment
240 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hip fracture